Health Technology Shionogi & Co., Ltd. Business Summary
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2023
JPY USD Revenue 426,684M 3,148.55M Gross Profit 356,580M 2,631.24M Operating income 160,551M 1,184.72M Income before tax 220,365M 1,626.10M Net income 184,965M 1,364.87M EBITDA 177,716M 1,311.38M Diluted EPS 621.09 4.58 Dividends Per Share 135 0.99 Total Assets 1,311.80B 9,856.48M Total liabilities 188,658M 1,417.52M Total equity 1,100.04B 8,265.42M Operating cash flow 177,867M 1,312.50M Currency in JPY Currency in USD
Historical Data Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
367,960M
333,371M
297,177M
335,138M
426,684M
Gross Profit
305,713M
270,117M
238,000M
272,411M
356,580M
Operating income
168,370M
130,609M
95,694M
111,480M
160,551M
Income before tax
174,043M
158,516M
143,018M
126,288M
220,365M
Net income
137,190M
122,193M
111,858M
114,185M
184,965M
EBITDA
187,074M
144,649M
110,403M
127,773M
177,716M
Diluted EPS
434.70
395.28
364.88
378.62
621.09
Dividends Per Share
94
103
108
115
135
Total Assets
938,540M
873,695M
998,992M
1,150.60B
1,311.80B
Total liabilities
125,125M
108,186M
134,156M
157,052M
188,658M
Total equity
808,774M
765,152M
846,108M
975,661M
1,100.04B
Operating cash flow
165,000M
131,940M
109,039M
102,068M
177,867M
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
3,318.10M
3,066.16M
2,802.03M
2,982.37M
3,148.55M
Gross Profit
2,756.78M
2,484.38M
2,244.06M
2,424.17M
2,631.24M
Operating income
1,518.28M
1,201.26M
902.28M
992.05M
1,184.72M
Income before tax
1,569.44M
1,457.94M
1,348.49M
1,123.83M
1,626.10M
Net income
1,237.11M
1,123.86M
1,054.69M
1,016.12M
1,364.87M
EBITDA
1,686.95M
1,330.40M
1,040.97M
1,137.04M
1,311.38M
Diluted EPS
3.92
3.63
3.44
3.36
4.58
Dividends Per Share
0.84
0.94
1.01
1.02
0.99
Total Assets
8,479.37M
8,093.14M
9,040.65M
9,479.72M
9,856.48M
Total liabilities
1,130.46M
1,002.13M
1,214.08M
1,293.94M
1,417.52M
Total equity
7,306.98M
7,087.69M
7,657.08M
8,038.40M
8,265.42M
Operating cash flow
1,487.89M
1,213.51M
1,028.11M
908.29M
1,312.50M
Valuation Measures
Mar 2023
PER 9.62 ROA 15.02% ROE 17.82% Operating margin 37.62% Profit margin 43.34%
Management
Chairman, Chief Executive Officer & President:
Isao Teshirogi
Manager-Accounting & Finance:
Yuji Hosogai
Senior Executive Officer & GM-Research:
Yasuetsu Imune
Senior Executive Officer, Head-R&D:
John Keller
Executive Officer & GM-Reliability Guarantee:
Takeshi Shiota Shareholders
Sumitomo Life Insurance Co. (6.0%)
Nomura Asset Management Co., Ltd. (5.9%)
Shionogi & Co., Ltd. (3.8%)
BlackRock Fund Advisors (3.1%)
Sumitomo Mitsui Banking Pension Fund (3.0%)
The Vanguard Group, Inc. (3.0%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.9%)
Nikko Asset Management Co., Ltd. (2.9%)
Nippon Life Insurance Co. (2.7%)
Daiwa Asset Management Co. Ltd. (2.7%)
Related Companies
Shionogi Srl
Shionogi infectious Disease research Foundation
Shionogi Singapore Pte Ltd.
Shionogi Marketing Solutions Co., Ltd.
Shionogi Pharmacovigilance Center Co., Ltd.
Shionogi Business Partner Co., Ltd.
Shionogi Digital Science Co., Ltd
Shionogi Career Development Center Co., Ltd.
Shionogi TechnoAdvance Research Co., Ltd.
Shionogi BV
Shionogi Pharma Co., Ltd.
Shionogi Healthcare Co. Ltd.
Shionogi & Co., Ltd. /2 Subsidiaries/
Shionogi & Co. Restricted Stock Compensation Plan
Pionnier KK
Shionogi USA Holdings, Inc.
Beijing Shionogi Pharmaceutical Technology Ltd.
Shionogi Ltd.
Ezose Sciences, Inc.
Shionogi Inc.
Shionogi Institute for Medical Science
Aburahi Laboratories
Taiwan Shionogi & Co., Ltd.
Shionogi Pharma Chemicals Co., Ltd.
Shionogi General Service Co., Ltd.
Shionogi Bunseki Center KK
Shionogi Ireland Ltd.
Shionogi Engineering Service Co. Ltd.
UMN Pharma, Inc.
Shionogi Bioresearch Corp.
Competitors
Nabriva Therapeutics Plc
Protara Therapeutics, Inc.
Vaxart, Inc.
Cocrystal Pharma Inc
TaiGen Biopharmaceuticals Holdings Limited
Trevi Therapeutics, Inc.
Spero Therapeutics, Inc.
Zynerba Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc.
Iterum Therapeutics plc
Atea Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc.
Arbutus Biopharma Corporation
Vir Biotechnology, Inc.
Cutia Therapeutics
Innoviva, Inc.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 21 Sep, 2023
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more